Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) (NCT05862012)
A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects With Relapsed/Refractory Multiple Myeloma
🩺 Plain-English Summary (8th-Grade Level)
This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma (R/R MM).
Who can join: Review the eligibility criteria below.
Location: Standford Cancer Institute — Palo Alto, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (32 Sites)
Showing the first 25 of 32 sites.
- Standford Cancer Institute — Palo Alto, California
- Sylvester Cancer Center — Miami, Florida
- Winship Cancer Institute — Atlanta, Georgia
- University of Chicago Medical Center — Chicago, Illinois
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Montefiore Medical Center — The Bronx, New York
- University of North Carolina — Chapel Hill, North Carolina
- Tennessee Oncology — Nashville, Tennessee
- Virginia Commonwealth University (VCU) — Richmond, Virginia
- Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin
- Concord Hospital — Concord, New South Wales
- Pindara Private Hospital — Benowa, Queensland
- St. Vincent's Hospital Melbourne — Fitzroy, Victoria
- Peter MacCallum Cancer Center — Melbourne, Victoria
- Linear Clinical Research — Nedlands, Western Australia
- CHRU Lille — Lille, Hauts-de-France
- CHU Poiters - Hospital la Miletrie — Poitiers, New Aquitaine
- CHU de Nantes - Hotel Dieu — Nantes, Pays de la Loire Region
- Groupe Hospitalier Pitie-Salpetriere — Paris, Île-de-France Region
- Apollo Hospital International Limited — Gandhinagar, Gujarat
- Health Care Global Enterprises Ltd. — Bangalore, Karnataka
- Deenanath Mangeshkar Hospital and Research Centre — Pune, Maharashta
- Apollo Cancer Centers — Hyderabad, Telangana
- HCG Hospital — Bangalore,
- ASST Spedali Civili di Brescia — Brescia, Lombardy
📞 Contact the Study Coordinator
Phone: (315) 583-1249
Email: clinicaltrials@ichnossciences.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Relapsed/Refractory Multiple Myeloma
- A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets — Stanford, California
- A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma — Little Rock, Arkansas
- Cevostamab Following CAR T Cell Therapy for RRMM — Philadelphia, Pennsylvania
- A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma — Clayton, North Carolina
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma — Birmingham, Alabama
- CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma — Birmingham, Alabama
Explore by condition: All Relapsed/Refractory Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.